Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
Background The predictive efficacy of current biomarker of immune checkpoint inhibitors (ICIs) is not sufficient. This study investigated the causality between radiomic biomarkers and immunotherapy response status in patients with stage IB–IV non-small cell lung cancer (NSCLC), including its biologi...
Main Authors: | Bin Xu, Lan Liu, Shaowei Wu, Guangyi Wang, Guibin Qiao, Weijie Zhan, Daipeng Xie, Lintong Yao, Henian Yao, Guoqing Liao, Luyu Huang, Yubo Zhou, Peimeng You, Zekai Huang, Qiaxuan Li, Siyun Wang, Dong-Kun Zhang, Lawrence Wing-Chi Chan, Michael Lanuti, Haiyu Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-10-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/10/e007369.full |
Similar Items
-
Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer
by: Qiaxuan Li, et al.
Published: (2021-10-01) -
Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma
by: Qiaxuan Li, et al.
Published: (2022-09-01) -
Homologous recombination repair rathway and RAD54L in early-stage lung adenocarcinoma
by: Shaopeng Zheng, et al.
Published: (2021-02-01) -
KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials
by: Hongyuan Zhu, et al.
Published: (2021-07-01) -
A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy
by: Bin Xu, et al.
Published: (2023-09-01)